153 related articles for article (PubMed ID: 38563851)
1. Real-world cost- effectiveness analysis: Tumor Treating Fields for newly diagnosed glioblastoma in China.
Xiang Y; Chen Y; Xu Z; Zhou S; Qin Z; Chen L; Xiao D; Liu S
J Neurooncol; 2024 Jun; 168(2):259-267. PubMed ID: 38563851
[TBL] [Abstract][Full Text] [Related]
2. Tumor treating fields and maintenance temozolomide for newly-diagnosed glioblastoma: a cost-effectiveness study.
Guzauskas GF; Pollom EL; Stieber VW; Wang BCM; Garrison LP
J Med Econ; 2019 Oct; 22(10):1006-1013. PubMed ID: 31050315
[No Abstract] [Full Text] [Related]
3. The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.
Garside R; Pitt M; Anderson R; Rogers G; Dyer M; Mealing S; Somerville M; Price A; Stein K
Health Technol Assess; 2007 Nov; 11(45):iii-iv, ix-221. PubMed ID: 17999840
[TBL] [Abstract][Full Text] [Related]
4. Tumor treating fields plus temozolomide for newly diagnosed glioblastoma: a sub-group analysis of Korean patients in the EF-14 phase 3 trial.
Kim CY; Paek SH; Nam DH; Chang JH; Hong YK; Kim JH; Kim OL; Kim SH
J Neurooncol; 2020 Feb; 146(3):399-406. PubMed ID: 32020470
[TBL] [Abstract][Full Text] [Related]
5. Estimated lifetime survival benefit of tumor treating fields and temozolomide for newly diagnosed glioblastoma patients.
Guzauskas GF; Salzberg M; Wang BC
CNS Oncol; 2018 Jul; 7(3):CNS23. PubMed ID: 30124334
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of the long-term use of temozolomide for treating newly diagnosed glioblastoma in Germany.
Waschke A; Arefian H; Walter J; Hartmann M; Maschmann J; Kalff R
J Neurooncol; 2018 Jun; 138(2):359-367. PubMed ID: 29468446
[TBL] [Abstract][Full Text] [Related]
7. Health-related quality of life, cognitive screening, and functional status in a randomized phase III trial (EF-14) of tumor treating fields with temozolomide compared to temozolomide alone in newly diagnosed glioblastoma.
Zhu JJ; Demireva P; Kanner AA; Pannullo S; Mehdorn M; Avgeropoulos N; Salmaggi A; Silvani A; Goldlust S; David C; Benouaich-Amiel A;
J Neurooncol; 2017 Dec; 135(3):545-552. PubMed ID: 28849310
[TBL] [Abstract][Full Text] [Related]
8. What is the Role of Tumor-treating Fields in Newly Diagnosed Glioblastoma?
Ornelas AS; Porter AB; Sharma A; Knox MG; Marks LA; Wingerchuk DM; O'Carroll CB
Neurologist; 2019 Mar; 24(2):71-73. PubMed ID: 30817495
[TBL] [Abstract][Full Text] [Related]
9. Economic evaluation of temozolomide in the treatment of recurrent glioblastoma multiforme.
Martikainen JA; Kivioja A; Hallinen T; Vihinen P
Pharmacoeconomics; 2005; 23(8):803-15. PubMed ID: 16097842
[TBL] [Abstract][Full Text] [Related]
10. Increased compliance with tumor treating fields therapy is prognostic for improved survival in the treatment of glioblastoma: a subgroup analysis of the EF-14 phase III trial.
Toms SA; Kim CY; Nicholas G; Ram Z
J Neurooncol; 2019 Jan; 141(2):467-473. PubMed ID: 30506499
[TBL] [Abstract][Full Text] [Related]
11. Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Stupp R; Taillibert S; Kanner AA; Kesari S; Steinberg DM; Toms SA; Taylor LP; Lieberman F; Silvani A; Fink KL; Barnett GH; Zhu JJ; Henson JW; Engelhard HH; Chen TC; Tran DD; Sroubek J; Tran ND; Hottinger AF; Landolfi J; Desai R; Caroli M; Kew Y; Honnorat J; Idbaih A; Kirson ED; Weinberg U; Palti Y; Hegi ME; Ram Z
JAMA; 2015 Dec; 314(23):2535-43. PubMed ID: 26670971
[TBL] [Abstract][Full Text] [Related]
12. Economic Evaluation of Bevacizumab for the First-Line Treatment of Newly Diagnosed Glioblastoma Multiforme.
Kovic B; Xie F
J Clin Oncol; 2015 Jul; 33(20):2296-302. PubMed ID: 26014296
[TBL] [Abstract][Full Text] [Related]
13. Tumor-treating fields plus chemotherapy versus chemotherapy alone for glioblastoma at first recurrence: a post hoc analysis of the EF-14 trial.
Kesari S; Ram Z;
CNS Oncol; 2017 Jul; 6(3):185-193. PubMed ID: 28399638
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of tumor-treating fields added to maintenance temozolomide in patients with glioblastoma: an updated evaluation using a partitioned survival model.
Connock M; Auguste P; Dussart C; Guyotat J; Armoiry X
J Neurooncol; 2019 Jul; 143(3):605-611. PubMed ID: 31127507
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of temozolomide for the treatment of newly diagnosed glioblastoma multiforme: a report from the EORTC 26981/22981 NCI-C CE3 Intergroup Study.
Lamers LM; Stupp R; van den Bent MJ; Al MJ; Gorlia T; Wasserfallen JB; Mittmann N; Jin Seung S; Crott R; Uyl-de Groot CA;
Cancer; 2008 Mar; 112(6):1337-44. PubMed ID: 18213621
[TBL] [Abstract][Full Text] [Related]
16. Subgroup economic analysis for glioblastoma in a health resource-limited setting.
Wu B; Miao Y; Bai Y; Ye M; Xu Y; Chen H; Shen J; Qiu Y
PLoS One; 2012; 7(4):e34588. PubMed ID: 22511951
[TBL] [Abstract][Full Text] [Related]
17. Tumor Treating Fields (TTFields) increase the effectiveness of temozolomide and lomustine in glioblastoma cell lines.
Fishman H; Monin R; Dor-On E; Kinzel A; Haber A; Giladi M; Weinberg U; Palti Y
J Neurooncol; 2023 May; 163(1):83-94. PubMed ID: 37131108
[TBL] [Abstract][Full Text] [Related]
18. The cost-effectiveness of temozolomide in the adjuvant treatment of newly diagnosed glioblastoma in the United States.
Messali A; Hay JW; Villacorta R
Neuro Oncol; 2013 Nov; 15(11):1532-42. PubMed ID: 23935155
[TBL] [Abstract][Full Text] [Related]
19. The effect of field strength on glioblastoma multiforme response in patients treated with the NovoTTF™-100A system.
Turner SG; Gergel T; Wu H; Lacroix M; Toms SA
World J Surg Oncol; 2014 May; 12():162. PubMed ID: 24884522
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
